An evaluation of the impact of MAPT, SNCA and APOE on the burden of Alzheimer's and Lewy body pathology

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 83, Issue 4, 2012, Pages 424-429

  Wider, Christian ^a,b   Ross, Owen A ^a   Nishioka, Kenya ^a   Heckman, Michael G ^b   Vilariño Güell, Carles ^a   Jasinska Myga, Barbara ^a,c   Erketin Taner, Nilufer ^a   Rademakers, Rosa ^a   Graff Radford, Neill R ^b   Mash, Deborah C ^d   Papapetropoulos, Spiridon ^d   Duara, Ranjan ^e   Uchikado, Hirotake ^b   Wszolek, Zbigniew K ^b   Farrer, Matthew J ^a   Dickson, Dennis W ^b  

^a MAYO GRADUATE SCHOOL   (United States)

^b MAYO CLINIC   (United States)

^c MEDICAL UNIVERSITY OF SILESIA   (Poland)

^d UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^e MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3' UNTRANSLATED REGION; AGED; ALLELE; ALPHA SYNUCLEIN GENGE; ALZHEIMER DISEASE; APOLIPOPROTEIN E EPSILON4 GENE; ARTICLE; BRAIN REGION; BRAIN WEIGHT; CONTROLLED STUDY; DIFFUSE LEWY BODY DISEASE; FEMALE; GENETIC ASSOCIATION; GENETIC RISK; HAPLOTYPE; HUMAN; HUMAN TISSUE; MALE; MAPT H1 GENE; MUTATOR GENE; NEUROFIBRILLARY TANGLE; NEUROPATHOLOGY; PARKINSON DISEASE; PRIORITY JOURNAL; SENILE PLAQUE; SINGLE NUCLEOTIDE POLYMORPHISM;

AGED, 80 AND OVER; ALPHA-SYNUCLEIN; ALZHEIMER DISEASE; APOLIPOPROTEINS E; BRAIN; FEMALE; HAPLOTYPES; HUMANS; LEWY BODIES; LEWY BODY DISEASE; MALE; ORGAN SIZE; PARKINSON DISEASE; POLYMORPHISM, SINGLE NUCLEOTIDE; TAU PROTEINS;

EID: 84857992834     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp-2011-301413     Document Type: Article

References (40)

1. Dickson DW. Tau and synuclein and their role in neuropathology. Brain Pathol 1999;9:657-61. (Pubitemid 29470959)
2. Galpern WR, Lang AE. Interface between tauopathies and synucleinopathies: a tale of two proteins. Ann Neurol 2006;59:449-58. (Pubitemid 43358065)
3. Buee L, Delacourte A. Comparative biochemistry of tau in progressive supranuclear palsy, corticobasal degeneration, FTDP-17 and Pick's disease. Brain Pathol 1999;9:681-93. (Pubitemid 29470961)
4. Braak H, Muller CM, Rub U, et al. Pathology associated with sporadic Parkinson's disease - where does it end? J Neural Transm Suppl 2006;70:89-97. (Pubitemid 44622184)
5. Scarmeas N, Hadjigeorgiou GM, Papadimitriou A, et al. Motor signs during the course of Alzheimer disease. Neurology 2004;63:975-82. (Pubitemid 39287903)
6. Aarsland D, Andersen K, Larsen JP, et al. Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch Neurol 2003;60:387-92. (Pubitemid 36314364)
7. Uchikado H, Lin WL, DeLucia MW, et al. Alzheimer disease with amygdala Lewy bodies: a distinct form of alpha-synucleinopathy. J Neuropathol Exp Neurol 2006;65:685-97. (Pubitemid 44297259)
8. Mikolaenko I, Pletnikova O, Kawas CH, et al. Alpha-synuclein lesions in normal aging, Parkinson disease, and Alzheimer disease: evidence from the Baltimore Longitudinal Study of Aging (BLSA). J Neuropathol Exp Neurol 2005;64:156-62. (Pubitemid 40349314)
9. Pletnikova O, West N, Lee MK, et al. Abeta deposition is associated with enhanced cortical alpha-synuclein lesions in Lewy body diseases. Neurobiol Aging 2005;26:1183-92. (Pubitemid 40726011)
10. Fujishiro H, Tsuboi Y, Lin WL, et al. Co-localization of tau and alpha-synuclein in the olfactory bulb in Alzheimer's disease with amygdala Lewy bodies. Acta Neuropathol 2008;116:17-24.
11. Muntane G, Dalfo E, Martinez A, et al. Phosphorylation of tau and alpha-synuclein in synaptic-enriched fractions of the frontal cortex in Alzheimer's disease, and in Parkinson's disease and related alpha- synucleinopathies. Neuroscience 2008;152:913-23.
12. Gallardo G, Schluter OM, Sudhof TC. A molecular pathway of neurodegeneration linking alpha-synuclein to ApoE and Abeta peptides. Nat Neurosci 2008;11:301-8. (Pubitemid 351311805)
13. Giasson BI, Forman MS, Higuchi M, et al. Initiation and synergistic fibrillization of tau and alpha-synuclein. Science 2003;300:636-40. (Pubitemid 36520587)
14. Duda JE, Giasson BI, Mabon ME, et al. Concurrence of alpha-synuclein and tau brain pathology in the Contursi kindred. Acta Neuropathol 2002;104:7-11. (Pubitemid 36075353)
15. Ross OA, Toft M, Whittle AJ, et al. Lrrk2 and Lewy body disease. Ann Neurol 2006;59:388-93. (Pubitemid 43202496)
16. Polvikoski T, Sulkava R, Haltia M, et al. Apolipoprotein E, dementia, and cortical deposition of beta-amyloid protein. N Engl J Med 1995;333:1242-7.
17. Josephs KA, Tsuboi Y, Cookson N, et al. Apolipoprotein E epsilon 4 is a determinant for Alzheimer-type pathologic features in tauopathies, synucleinopathies, and frontotemporal degeneration. Arch Neurol 2004;61:1579-84. (Pubitemid 39350269)
18. Farrer MJ. Genetics of Parkinson disease: paradigm shifts and future prospects. Nat Rev Genet 2006;7:306-18.
19. Peuralinna T, Oinas M, Polvikoski T, et al. Neurofibrillary tau pathology modulated by genetic variation of alpha-synuclein. Ann Neurol 2008;64:348-52.
20. Houlden H, Baker M, Morris HR, et al. Corticobasal degeneration and progressive supranuclear palsy share a common tau haplotype. Neurology 2001;56:1702-6. (Pubitemid 32574570)
21. Goris A, Williams-Gray CH, Clark GR, et al. Tau and alpha-synuclein in susceptibility to, and dementia in, Parkinson's disease. Ann Neurol 2007;62:145-53. (Pubitemid 47546500)
22. Wider C, Vilarino-Guell C, Jasinska-Myga B, et al. Association of the MAPT locus with Parkinson's disease. Eur J Neurol 2010;17:483-6.
23. Khachaturian ZS. Diagnosis of Alzheimer's disease. Arch Neurol 1985;42:1097-105. (Pubitemid 16236926)
24. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 1991;82:239-59.
25. Jellinger KA, Attems J. Incidence of cerebrovascular lesions in Alzheimer's disease: a postmortem study. Acta Neuropathol 2003;105:14-17. (Pubitemid 36789951)
26. Myers AJ, Kaleem M, Marlowe L, et al. The H1c haplotype at the MAPT locus is associated with Alzheimer's disease. Hum Mol Genet 2005;14:2399-404. (Pubitemid 41418001)
27. Westfall PH, Young SS. Resampling-based multipletesting: examples and methods for p-value adjustment. New York: John Wiley and Sons, 1993.
28. Lambert JC, Heath S, Even G, et al. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat Genet 2009;41:1094-9.
29. Harold D, Abraham R, Hollingworth P, et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet 2009;41:1088-93.
30. Bertram L, McQueen M, Mullin K, et al. The AlzGene Database. Alzheimer Research Forum (available at: http://www.alzgene.org). http://www.alzgene.org/ meta.asp?geneID=232
31. Myers AJ, Pittman AM, Zhao AS, et al. The MAPT H1c risk haplotype is associated with increased expression of tau and especially of 4 repeat containing transcripts. Neurobiol Dis 2007;25:561-70.
32. Kwok JB, Teber ET, Loy C, et al. Tau haplotypes regulate transcription and are associated with Parkinson's disease. Ann Neurol 2004;55:329-34. (Pubitemid 38269584)
33. Kwok JB, Hallupp M, Loy CT, et al. GSK3B polymorphisms alter transcription and splicing in Parkinson's disease. Ann Neurol 2005;58:829-39. (Pubitemid 41746872)
34. Kwok JB, Loy CT, Hamilton G, et al. Glycogen synthase kinase-3beta and tau genes interact in Alzheimer's disease. Ann Neurol 2008;64:446-54.
35. Dickson DW, Crystal HA, Bevona C, et al. Correlations of synaptic and pathological markers with cognition of the elderly. Neurobiol Aging 1995;16:285-98.
36. Halliday G, Hely M, Reid W, et al. The progression of pathology in longitudinally followed patients with Parkinson's disease. Acta Neuropathol 2008;115:409-15.
37. Braak H, Del Tredici K, Rub U, et al. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003;24:197-211. (Pubitemid 36007810)
38. de Silva R, Hardy J, Crook J, et al. The tau locus is not significantly associated with pathologically confirmed sporadic Parkinson's disease. Neurosci Lett 2002;330:201-3. (Pubitemid 35257899)
39. Bennett DA, Wilson RS, Schneider JA, et al. Apolipoprotein E epsilon4 allele, AD pathology, and the clinical expression of Alzheimer's disease. Neurology 2003;60:246-52. (Pubitemid 36152017)
40. Morris JC, Roe CM, Xiong C, et al. APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Ann Neurol 2010;67:122-31.